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OBJECTIVES: Mastitis is one of the most frequent and costly diseases in the dairy
industry with gram-negative bacteria being the main causal agent. Since most
antibiotics have minimal effect on shortening the duration of clinical mastitis
caused by gram-negative pathogens (gram-CM) and because of a high spontaneous
cure rate, antibiotics are often not recommended for treating Gram-CM. The pur-
pose of this study was to develop a model comparing 5-day treatment with ceftio-
fur hydrochloride to no treatment of gram-CM, also allowing easy adaptations to
reflect the high variability of prices and cost data in livestock. METHODS: A deci-
sion tree was developed in MS Excel considering first and recurrent CM episodes,
culling and death of cows with gram-CM. Cure rates and other clinical data were
derived from published studies. Costs and losses associated with CM and its treat-
ment, culled or dead cows as well as income generated from saleable milk produc-
tion or sold cows were considered. Cost and income values were derived from
public sources (US-2010, perspective of the producer). All input parameters were
varied extensively in one-way sensitivity analyses. RESULTS: With US-2010 cost/
prices, income from saleable milk was $3,039.35 (ceftiofur) and $3069.67 (no treat-
ment), and costs associated with the disease and treatment totaled to $215.12
(ceftiofur) and $246.60 (no treatment) over the entire lactation period, resulting in a
$1.16 higher margin per treated cow with a 5-day treatment with ceftiofur com-
pared to no treatment of gram-CM.More cowswere cured and fewer cows culled or
died with ceftiofur. The model was most sensitive to ceftiofur cure rate and self-
cure rate. CONCLUSIONS: Compared to no treatment, ceftiofur’s higher treatment
costs and less income due to milk discard were offset by a better efficacy, resulting
in less disease associated costs of gram-CM.
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OBJECTIVES: Data documenting the incremental economic and health burden of
HCV infections will be required to evaluate the comparative effectiveness of new,
emerging HCV therapies. Our objective is to estimate the incremental cost associ-
atedwith hepatitis C infections [HCV] in real-world clinical practice.METHODS: Six
years of de-identified data from a U.S. health insurer [2003-2008] were used to
identify patients with HCV with at least two years of data prior to and following
their first HCV diagnosis or the start of antiviral drug therapy [index date]. Non-
HCV patients with 2 years of eligibility were identified and patients with a pre-
index diagnosis for HIV, hepatitis B, cirrhosis, liver cancer or a liver transplantation
were excluded. Propensity score matching was used to match the patients with
HCV to similar non-HCV patients on a 1-to-1 ratio. The incremental impact of HCV
on post-index cost and adverse event risk were estimated controlling for patient
demographics, diagnostic profile, and prescription drug profile. RESULTS: The
8,861 HCV patients and 8,861matched non-HCV patients in the study sample were
60%male, age 50 years old. Post-index total cost of HCV andnon-HCVpatientswere
$37,390 and $13,575, respectively, in the first year. The incremental cost of HCVwas
estimated at$23,406 due primarily to higher costs for ambulatory care [$6,531],
hospital services [$1,827] and prescription drugs [$6,935]. HCV was associated
with higher risk of hospitalization [Odd Ratios (O.R.) 2.5]; depression [O.R.. 2.2];
cirrhosis [O.R. 65.8]; hepatic cancer [O.R. 28.1] and liver transplantation [O.R.
46.1] [p0.0001 for all estimates]. CONCLUSIONS: Newly diagnosed HCV patients
experience significantly higher cost and adverse event risk relative to matched
non-HCV patients. These results highlight the need for safe, tolerable and effective
antiviral therapies, and the need for risk predicting tools to identify HCVpatients at
high risk for adverse events.
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OBJECTIVES: Severe sepsis (SS) contributes to a high economic burden among
critically ill patients. The objective of the study was to describe SS population and
determine associated costs.METHODS: Data was drawn from a large IHS (Jan 2002
to Dec 2008) and included two groups of adult patients; SSD: SS or septic shock
ICD-9 code (995.92 and 785.52); and NSSD: SS criteria by Angus (2001) and Martin
(2003). Patients were evaluated at index hospitalization, 30-days (30D), 30-days-6-
months (30D-6M), and 6-months-1year (6M-1YR) post-discharge. Comorbidities,
antibiotic use, supportive treatment, mortality, and costs were analyzed. Costs
were adjusted to 2009 US Dollars using the overall urban CPI; 0.65 (cost-to-charge-
ratio) was applied to charge data. Follow-up cost analysis was limited to patients
with complete data at the beginning of each evaluation period. RESULTS: The
cohort included 17,256 patients: 3,229 (19%) SSD and 14,027 (81%) NSSD. The groups
had similar baseline demographics and comorbidities. SSD had a higher rate of ICU
admission (81% vs. 47%). Nearly all received antibiotics. Supportive treatments
included vasopressors (66% vs. 19%) and mechanical ventilation (71% vs. 39%).
Mean length of stay (LOS) was 212d for SSD and 1414d for NSSD. Hospital mor-
tality was 40% for SSD and 11% for NSSD; overall mortality at 1-year pdschg was
61% and 39%, respectively. Mean cost of hospitalization was $75K107K, with
SSD costing almost double NSSD ($123K149K vs. $64K$91K). In all three fol-
low-up periods, NSSD incurred higher costs ($18K34K vs. $14K27K for 30D,
$54K102K vs. $42K81K for 30D-6M, and $34K67K vs. $27K56K for 6M-1YR.
CONCLUSIONS: SSD patients have higher rates of mortality, both during hospital-
ization and in the year following, compared to NSSD patients. The higher mean
hospitalization costs for SSD may be due to longer LOS/ more intensive resource
use. The lower overall 1-yearmortality rate in NSSDmay be associated with higher
follow-up costs.
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OBJECTIVES: The treatment of surgical site infections (SSI) is associated with high
costs for the statutory health insurance (SHI) and for hospitals. The DRG-reim-
bursement for septic revisions seems to be not cost-covering for hospitals.Without
an Arthroplasty Register for Germany, exact numbers for SSI in hip arthroplasty
and knee arthroplasty are not available. Also there is no approximation for the
financial impact, yet. The purpose of this work is to estimate the financial impact
and possible risk of SSI in knee and hip arthroplasty for SHI and hospitals.
METHODS: To estimate the number of SSI for Germany, a projection for all SSI in
primary hip and knee replacements in Germany (N372.851) was made with data
from the KISS module surgical (“Krankenhaus-Infektions-Surveillance-System”).
Two approaches were used to assess the costs: First, treatment expenses from the
Barmer GEK-report were used and second a bottom-up analysis based on themed-
ical and pharmaceutical costs of the treatment algorithm for SSI. RESULTS: The
revision treatment of SSI resulted in a financial burden of at least € 22.407.350 for
hip replacement and € 13.760.280 for knee replacement for the SHI. Due to the even
higher medical and pharmaceutical costs for the treatment of SSI in hospitals, SSI
can cause a financial loss to them. CONCLUSIONS: To achieve a cost-covering
treatment of SSI in hospitals, the severalmethods of reducing the risk of SSI should
be checked with a cost-minimization-analysis. Then, hospitals have the opportu-
nity to calculate the risk of higher SSI-rates against higher costs for primary re-
placement with a reduced risk of SSI. For the SHI a cost-benefit-analysis could be
helpful to make a decision about requirements on methods used in primary re-
placement in hospitals to reduce the rate off SSI. A German Arthroplasty Register
should include the collection of SSI data in its dataset.
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OBJECTIVES: In Canada, nosocomial pneumonia (NP) and complicated skin and
soft tissue infection (CSSTI) caused by MRSA are often treated with antibiotics
administered in hospital, with a follow-up course administered at home for stable
patients. Typically, IV vancomycin is used when MRSA is the proven or suspected
pathogen. Our objective was to evaluate the potential treatment cost impact using
oral (PO) linezolid vs. IV vancomycin for NP and CSSTI therapy, using a Net Impact
Analysis approach for Quebec.METHODS: Data on healthcare resource utilization
associated with linezolid and vancomycin therapy were collected for patients with
NP or CSSTI in Quebec. Costs were assigned to healthcare resources (antibiotics,
medical supplies, laboratory testing and healthcare professionals’ time) based on
unit prices. Based on expert opinion, analyses assumed IV vancomycin is admin-
istered in hospital for an average of 10 or 5 days followed by 11 or 9 days at home for
NP or CSSTI, respectively, whereas linezolid is administered in hospital for 5 or 2
days IV then 5 or 3 days PO, followed by 11 or 9 days PO at home for NP or CSSTI,
respectively. RESULTS: Antibiotic acquisition costs were higher for linezolid than
for vancomycin, both in hospital (Can$1,696.20 vs. $186.00 and $822.72 vs. $93.00
for NP and CSSTI, respectively) and for home therapy ($1,655.30 vs. $1,531.05 and
$1,355.87 vs. $1,242.08 for NP and CSSTI, respectively). However, total treatment
costs including costs for preparing, administering andmonitoring drug levels were
lower for linezolid vs. vancomycin, thus offsetting drug acquisition costs (total
treatment costs: $6,582.62 vs. $7,599.00 and $3,849.80 vs. $5,141.02 for NP and
CSSTI, respectively). CONCLUSIONS: In this net impact study, using linezolid com-
pared to vancomycin to treat NP and CSSTI, for hospital and home courses com-
bined, reduces healthcare resource utilization and costs.
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OBJECTIVES: Guidelines recommend that patients with HIV infection who are
naïve to treatment receive two nucleoside reverse transcriptase inhibitors (NRTI)
plus a third agent which may be a non nucleoside reverse transcriptase inhibitor
(NNRTI), protease inhibitor (PI), or integrase inhibitor (II). This study examined
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